HIV Pol-derived peptide-MHC class I complex (HIV Pol-pMHC-I) (HIV Pol-pMHC-I)

HIV Pol-derived peptides presented on MHC class I molecules are essential targets for the immune system's effort to control HIV-1 infection. The Pol polyprotein, which encodes reverse transcriptase, integrase, and protease, is relatively conserved across different viral strains, making its epitopes attractive for therapeutic targeting to minimize viral escape (Walker & Yu, 2013, Nature Reviews Immunology). These peptides are generated through proteasomal degradation of viral proteins and are subsequently transported into the endoplasmic reticulum, where they bind to MHC class I molecules for surface expression (Neefjes et al., 2011, Nature Reviews Immunology). Once presented, these complexes are recognized by specific CD8+ T-cell receptors (TCRs), triggering the release of cytotoxic granules and cytokines to destroy the infected cell (Goulder & Watkins, 2008, Nature Reviews Immunology). Modern therapeutic approaches leverage this interaction through the use of TCR-engineered T cells, therapeutic vaccines, and bispecific T-cell engagers like ImmTAVs, which redirect T cells to kill HIV-infected cells (Yang et al., 2016, Molecular Therapy). Despite their potential, the effectiveness of these therapies is often limited by the high genetic diversity of HIV and the requirement for specific HLA alleles in the patient population (Korber et al., 2009, Expert Review of Vaccines).

Other names

HIV Pol-HLA complexHIV-1 Pol epitope-MHC class I complexHIV Pol-derived peptides presented by HLA class I

Recognition of the peptide-MHC complex by natural or engineered T-cell receptors (TCRs), leading to the activation of cytotoxic T lymphocytes and the targeted lysis of HIV-infected cells.